Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Apixaban. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 known ✓ | P00742 | 20/20 | 0.98 |
| ▸ | F2 | P00734 | 5/20 | 0.98 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Apixaban SCHEMBL5445904 | 1.00 | F10 (0.98) | F10F2SLC29A1 | |
| Apixaban SCHEMBL118023 | 0.99 | F10 (1.00) | F10F2SLC29A1 | |
| SCHEMBL19086463 | 0.98 | F10 (0.98) | F10F2SLC29A1 | |
| Apixaban SCHEMBL14672486 | 0.98 | F10 (0.98) | F10F2SLC29A1 | |
| SCHEMBL16730331 | 0.96 | F10 (0.94) | F10F2SLC29A1 | |
| Apixaban SCHEMBL28348493 | 0.95 | F10 (0.93) | F10F2SLC29A1 | |
| Apixaban SCHEMBL19991448 | 0.95 | F10 (0.93) | F10F2SLC29A1 | |
| Apixaban SCHEMBL13321443 | 0.94 | F10 (0.91) | F10F2SLC29A1 | |
| Apixaban SCHEMBL22581184 | 0.94 | F10 (0.90) | F10F2SLC29A1 | |
| Apixaban SCHEMBL31267125 | 0.93 | F10 (0.88) | F10F2SLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110452240-B | Apixaban crystal form and preparation method thereof | 广州白云山天心制药股份有限公司 | 2021-10-26 | — | — | CN | disclosed |
| US-10040793-B2 | Key intermediates and impurities of the synthesis of Apixaban: Apixaban glycol esters | F.I.S. FABBRICA ITALIANA SINTETICI S.P.A. (IT) | 2018-08-07 | — | — | US | disclosed |
| US-20180086759-A1 | KEY INTERMEDIATES AND IMPURITIES OF THE SYNTHESIS OF APIXABAN: APIXABAN GLYCOL ESTERS | FIS FABBRICA ITALIANA SINTETICI SPA (IT) | 2018-03-29 | — | — | US | disclosed |
| US-9920051-B2 | Key intermediates and impurities of the synthesis of apixaban: apixaban glycol esters | F.I.S.—Fabbrica Italiana Sintetici S.p.A. (IT) | 2018-03-20 | — | — | US | disclosed |
| EP-3098221-B1 | PROCESS FOR PREPARING APIXABAN FORM N-1 | F I S - FABBRICA ITALIANA SINTETICI S P A (IT) | 2017-12-06 | — | — | EP | disclosed |
| US-9624221-B2 | Key intermediates and impurities of the synthesis of Apixaban: Apixaban glycol esters | F.I.S.—FABBRICA ITALIANA SINTETICI S.P.A (IT) | 2017-04-18 | — | — | US | disclosed |
| US-20170001999-A1 | KEY INTERMEDIATES AND IMPURITIES OF THE SYNTHESIS OF APIXABAN: APIXABAN GLYCOL ESTERS | F.I.S. - FABBRICA ITALIANA SINTETICI S.P.A. (IT) | 2017-01-05 | — | — | US | disclosed |
| EP-3098221-A1 | PROCESS FOR PREPARING APIXABAN FORM N-1 | F.I.S.- Fabbrica Italiana Sintetici S.p.A. (IT) | 2016-11-30 | — | — | EP | disclosed |
| US-20160326171-A1 | KEY INTERMEDIATES AND IMPURITIES OF THE SYNTHESIS OF APIXABAN: APIXABAN GLYCOL ESTERS | F I S - FABBRICA ITALIANA SINTETICI S P A (IT) | 2016-11-10 | — | — | US | disclosed |
| EP-3009435-B1 | Apixaban glycol esters as key intermediates and impurities of the synthesis of Apixaban | ITALIANA SINT SPA (IT) | 2016-08-17 | — | — | EP | disclosed |
| WO-2016058711-A1 | KEY INTERMEDIATES AND IMPURITIES OF THE SYNTHESIS OF APIXABAN: APIXABAN GLYCOL ESTERS | F.I.S. - FABBRICA ITALIANA SINTETICI S.P.A. (IT) | 2016-04-21 | — | — | WO | disclosed |
| EP-3009435-A1 | Apixaban glycol esters as key intermediates and impurities of the synthesis of Apixaban | F.I.S.- Fabbrica Italiana Sintetici S.p.A. (IT) | 2016-04-20 | — | — | EP | disclosed |
| US-20150272891-A1 | DOSAGE FORMS COMPRISING APIXABAN AND MATRIX FORMER | RATIOPHARM GMBH (DE) | 2015-10-01 | — | — | US | disclosed |
| EP-2854759-A1 | DOSAGE FORMS COMPRISING APIXABAN AND MATRIX FORMER | ratiopharm GmbH (DE) | 2015-04-08 | — | — | EP | disclosed |
| WO-2013174498-A1 | DOSAGE FORMS COMPRISING APIXABAN AND MATRIX FORMER | RATIOPHARM GMBH (DE) | 2013-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160326171-A1 | KEY INTERMEDIATES AND IMPURITIES OF THE SYNTHESIS OF APIXABAN: APIXABAN GLYCOL ESTERS | CYP2C9, VKORC1, CYP3A4 | F10 10/4885F2 55/4885SLC29A1 2948/4885 |
| US-20180086759-A1 | KEY INTERMEDIATES AND IMPURITIES OF THE SYNTHESIS OF APIXABAN: APIXABAN GLYCOL ESTERS | CYP2C9, VKORC1, CYP3A4 | F10 10/4885F2 55/4885SLC29A1 2948/4885 |
| US-20170001999-A1 | KEY INTERMEDIATES AND IMPURITIES OF THE SYNTHESIS OF APIXABAN: APIXABAN GLYCOL ESTERS | CYP2C9, VKORC1, CYP3A4 | F10 16/4885F2 54/4885SLC29A1 2283/4885 |
| US-20150272891-A1 | DOSAGE FORMS COMPRISING APIXABAN AND MATRIX FORMER | VKORC1, VKORC1L1, PROC | F10 9/4885F2 4/4885SLC29A1 3353/4885 |
| US-10040793-B2 | Key intermediates and impurities of the synthesis of Apixaban: Apixaban glycol esters | CYP2C9, VKORC1, CYP3A4 | F10 10/4885F2 55/4885SLC29A1 2948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.